MeSH term
Frequency | Condition_Probility | Aged | 32 | 0.0 |
Aged, 80 and over | 6 | 0.0 |
Fatal Outcome | 2 | 0.0 |
Female | 58 | 0.0 |
Humans | 146 | 0.0 |
Animals | 47 | 0.0 |
Amino Acid Sequence | 13 | 0.0 |
Cloning, Molecular | 8 | 0.0 |
Immunoblotting | 9 | 0.0 |
Mice | 13 | 0.0 |
Rats | 8 | 0.0 |
Tumor Cells, Cultured | 2 | 0.0 |
Base Sequence | 11 | 0.0 |
Comparative Study | 13 | 0.0 |
Eye Proteins/*genetics | 3 | 1.0 |
Molecular Sequence Data | 18 | 0.0 |
Phosphoproteins/*genetics | 3 | 1.0 |
Polymerase Chain Reaction | 2 | 0.0 |
Research Support, Non-U.S. Gov't | 83 | 0.0 |
Adolescent | 8 | 0.0 |
Adult | 42 | 0.0 |
Cattle | 10 | 0.0 |
Fluorescent Antibody Technique, Indirect | 5 | 0.0 |
Male | 58 | 0.0 |
Middle Aged | 39 | 0.0 |
Mitochondria, Liver/enzymology/*immunology | 4 | 80.0 |
Pyruvate Dehydrogenase Complex/immunology | 6 | 85.0 |
*Energy Metabolism | 2 | 2.0 |
Exercise/*physiology | 5 | 1.0 |
Exercise Test | 2 | 0.0 |
Kinetics | 13 | 0.0 |
Oxygen Consumption | 2 | 0.0 |
Pyruvate Dehydrogenase Complex/metabolism | 8 | 44.0 |
Enzyme-Linked Immunosorbent Assay | 10 | 0.0 |
Mitochondria/immunology | 6 | 46.0 |
Diagnosis, Differential | 4 | 0.0 |
Gene Expression | 2 | 0.0 |
Immunohistochemistry | 4 | 0.0 |
Genetic Predisposition to Disease | 2 | 0.0 |
Guam/epidemiology | 4 | 66.0 |
Research Support, U.S. Gov't, P.H.S. | 45 | 0.0 |
Autoantigens/*immunology | 9 | 5.0 |
*Immune Tolerance | 2 | 1.0 |
Liver Cirrhosis, Biliary/*immunology | 13 | 37.0 |
Phenotype | 2 | 0.0 |
Pyruvate Dehydrogenase Complex/*immunology | 18 | 94.0 |
Acetylation | 8 | 1.0 |
Binding Sites | 4 | 0.0 |
Gene Expression Regulation, Enzymologic | 3 | 0.0 |
Mutagenesis, Site-Directed | 6 | 0.0 |
Mutation | 2 | 0.0 |
Oxidation-Reduction | 8 | 0.0 |
Phosphorylation | 7 | 0.0 |
Protein Structure, Tertiary | 4 | 0.0 |
Pyruvate Dehydrogenase Complex/chemistry/genetics/*metabolism | 2 | 100.0 |
Thiamine Pyrophosphate/metabolism | 4 | 80.0 |
Age of Onset | 2 | 0.0 |
Temperature | 2 | 0.0 |
Guam | 16 | 94.0 |
Parkinson Disease/*metabolism | 2 | 7.0 |
Dendritic Cells/*physiology | 4 | 5.0 |
Interferon-alpha/biosynthesis | 3 | 12.0 |
Viral Load | 2 | 0.0 |
Brain/*pathology/ultrastructure | 2 | 20.0 |
Microscopy, Electron | 4 | 0.0 |
Parkinson Disease/pathology | 2 | 33.0 |
Th1 Cells/immunology | 2 | 1.0 |
Pyruvate Dehydrogenase Complex Deficiency Disease/*genetics | 2 | 100.0 |
Retrospective Studies | 2 | 0.0 |
Survival Rate | 2 | 0.0 |
Prospective Studies | 2 | 0.0 |
CD4-Positive T-Lymphocytes/immunology | 2 | 0.0 |
Cells, Cultured | 12 | 0.0 |
*Drosophila Proteins | 3 | 0.0 |
Lymphocyte Activation | 8 | 0.0 |
Flow Cytometry | 4 | 0.0 |
Dendritic Cells/*immunology | 2 | 0.0 |
Statistics, Nonparametric | 3 | 0.0 |
Amyotrophic Lateral Sclerosis/*pathology | 4 | 28.0 |
Dementia/*pathology | 4 | 28.0 |
Dihydrolipoamide Dehydrogenase/metabolism | 2 | 50.0 |
Protein Binding | 2 | 0.0 |
Pyruvic Acid/metabolism | 3 | 37.0 |
Thermodynamics | 2 | 0.0 |
Glucose/metabolism | 4 | 1.0 |
Isoenzymes/metabolism | 3 | 0.0 |
Kidney/enzymology | 2 | 1.0 |
Lactic Acid/metabolism | 2 | 7.0 |
Liver/enzymology | 3 | 0.0 |
Protein Kinases/metabolism | 2 | 0.0 |
Receptors, Cytoplasmic and Nuclear/metabolism | 2 | 1.0 |
Transcription Factors/metabolism | 2 | 0.0 |
Autoantibodies/*analysis | 4 | 1.0 |
Mitochondria, Liver/immunology | 4 | 50.0 |
Time Factors | 5 | 0.0 |
Antibodies, Monoclonal/immunology | 2 | 0.0 |
Autoantibodies/*immunology | 6 | 2.0 |
Epitopes | 6 | 0.0 |
Mice, Inbred BALB C | 4 | 0.0 |
Mitochondria/*immunology | 4 | 50.0 |
Biological Availability | 2 | 0.0 |
Child | 8 | 0.0 |
Sensitivity and Specificity | 4 | 0.0 |
Treatment Outcome | 4 | 0.0 |
Child, Preschool | 7 | 0.0 |
Energy Intake | 2 | 1.0 |
Infant | 7 | 0.0 |
Infant, Newborn | 4 | 0.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 4 | 0.0 |
Sequence Alignment | 3 | 0.0 |
Autoantibodies/blood | 4 | 2.0 |
Liver Cirrhosis, Biliary/diagnosis/*immunology | 2 | 66.0 |
Autoantigens/immunology | 4 | 2.0 |
Liver Cirrhosis, Biliary/*immunology/physiopathology | 2 | 100.0 |
Pyruvate Dehydrogenase Complex/genetics/*metabolism | 2 | 66.0 |
Liver Cirrhosis, Biliary/*immunology/pathology | 2 | 33.0 |
Mice, Inbred Strains | 2 | 0.0 |
Acetylcarnitine/metabolism | 3 | 75.0 |
Carnitine/metabolism | 2 | 28.0 |
Enzyme Activation/drug effects | 2 | 0.0 |
Glycogen/metabolism | 2 | 4.0 |
Pyruvate Dehydrogenase Complex/*metabolism | 10 | 55.0 |
Autoantibodies/immunology | 4 | 3.0 |
Autoimmunity | 3 | 2.0 |
Liver Cirrhosis, Biliary/genetics/*immunology | 3 | 60.0 |
Fluorescent Antibody Technique | 3 | 0.0 |
Parkinsonian Disorders/*pathology | 2 | 100.0 |
tau Proteins/analysis | 2 | 14.0 |
Antibody Specificity | 4 | 0.0 |
Apoptosis | 3 | 0.0 |
Autoimmune Diseases/*immunology | 3 | 1.0 |
Immunization | 2 | 0.0 |
Brain/pathology | 4 | 1.0 |
Dementia/*complications/pathology | 2 | 100.0 |
Parkinsonian Disorders/*complications/pathology | 2 | 100.0 |
English Abstract | 4 | 0.0 |
Acute Disease | 2 | 0.0 |
Cell Differentiation | 2 | 0.0 |
Severity of Illness Index | 4 | 0.0 |
Amyotrophic Lateral Sclerosis/*physiopathology | 2 | 33.0 |
Dementia/*physiopathology | 2 | 25.0 |
Macromolecular Substances | 4 | 0.0 |
Mitochondria/*enzymology | 2 | 1.0 |
Molecular Weight | 4 | 0.0 |
Saccharomyces cerevisiae/enzymology | 2 | 3.0 |
Sequence Deletion | 3 | 0.0 |
Sequence Homology, Amino Acid | 4 | 0.0 |
Antibody Formation | 2 | 0.0 |
Cross Reactions | 3 | 0.0 |
Cytokines/biosynthesis | 3 | 0.0 |
Liver Cirrhosis, Biliary/enzymology/*immunology | 5 | 100.0 |
Spleen/immunology | 2 | 1.0 |
3-Methyl-2-Oxobutanoate Dehydrogenase (Lipoamide) | 3 | 18.0 |
Blotting, Northern | 2 | 0.0 |
Pyruvate Dehydrogenase Complex/*genetics | 3 | 21.0 |
RNA, Messenger/genetics | 2 | 0.0 |
Autoantibodies/*blood | 2 | 0.0 |
Cell Line | 3 | 0.0 |
Escherichia coli | 2 | 0.0 |
Open Reading Frames | 2 | 0.0 |
Peptides/genetics/*immunology | 2 | 50.0 |
Pyruvate Dehydrogenase Complex/genetics/*immunology | 2 | 100.0 |
Recombinant Proteins/immunology | 2 | 0.0 |
Myocardium/enzymology | 7 | 8.0 |
Swine | 8 | 0.0 |
*Autoantigens | 2 | 5.0 |
Peptide Fragments/immunology | 4 | 1.0 |
T-Lymphocytes/*immunology | 5 | 0.0 |
Immunophenotyping | 4 | 0.0 |
Oligodeoxyribonucleotides/pharmacology | 3 | 12.0 |
Dichloroacetate/pharmacology | 2 | 66.0 |
Immunoglobulins, Fab/immunology | 2 | 1.0 |
Recombinant Proteins | 2 | 0.0 |
Reference Values | 2 | 0.0 |
Peptides/immunology | 2 | 1.0 |
Syndrome | 4 | 0.0 |
Blotting, Western | 4 | 0.0 |
Electrophoresis, Polyacrylamide Gel | 5 | 0.0 |
Pyruvate Dehydrogenase Complex/*analysis | 3 | 100.0 |
Chromatography, Affinity | 2 | 0.0 |
Epitopes/*immunology | 3 | 1.0 |
Liver Cirrhosis, Biliary/blood/*immunology | 3 | 42.0 |
*Pyruvate Dehydrogenase Complex | 2 | 50.0 |
RNA, Messenger/metabolism | 2 | 0.0 |
Autoantibodies/blood/*immunology | 2 | 5.0 |
Acetyl Coenzyme A/metabolism | 3 | 18.0 |
Oxygen Consumption/physiology | 2 | 2.0 |
Chromosome Mapping | 2 | 0.0 |
Ketoglutarate Dehydrogenase Complex/metabolism | 2 | 28.0 |
Muscle, Skeletal/enzymology | 2 | 4.0 |
Pedigree | 4 | 0.0 |
Binding Sites, Antibody | 2 | 0.0 |
Rabbits | 3 | 0.0 |
Autoantigens/*analysis | 2 | 9.0 |
Epithelial Cells/immunology | 2 | 5.0 |
Guam/ethnology | 2 | 100.0 |
Epitopes/immunology | 4 | 0.0 |
Enzyme Activation | 3 | 0.0 |
Pyruvate Dehydrogenase (Lipoamide)-Phosphatase/metabolism | 2 | 66.0 |
Case-Control Studies | 3 | 0.0 |
Antigen-Antibody Reactions | 2 | 0.0 |
Ketoglutarate Dehydrogenase Complex/immunology | 2 | 100.0 |
Liver/immunology/pathology | 2 | 11.0 |
Thioctic Acid/metabolism | 2 | 66.0 |
Leukocyte Count | 2 | 0.0 |
Lod Score | 2 | 0.0 |
Muscles/enzymology | 2 | 3.0 |
NAD/metabolism | 2 | 3.0 |
Transplantation, Homologous | 3 | 0.0 |
Protein Processing, Post-Translational | 2 | 0.0 |
RNA, Messenger/biosynthesis | 3 | 0.0 |
Sequence Homology, Nucleic Acid | 2 | 0.0 |
Species Specificity | 2 | 0.0 |
Muscles/*metabolism | 2 | 2.0 |
Autoantibodies/*blood/immunology | 2 | 8.0 |
Amyotrophic Lateral Sclerosis/*metabolism | 2 | 11.0 |
Mitochondria/enzymology/immunology | 2 | 66.0 |
Autoantibodies/biosynthesis | 2 | 5.0 |
Alzheimer Disease/*complications | 2 | 100.0 |
Analysis of Variance | 2 | 0.0 |
Dementia/*complications | 2 | 50.0 |
Nervous System Diseases/*complications/physiopathology | 2 | 100.0 |
Neuropsychological Tests | 2 | 0.0 |
Parkinson Disease/*complications | 2 | 50.0 |
Pattern Recognition, Visual | 2 | 25.0 |
*Smell | 2 | 50.0 |
Mitochondria, Heart/*enzymology | 2 | 25.0 |
Ketoglutarate Dehydrogenase Complex/*metabolism | 2 | 66.0 |
Pyruvates/metabolism | 3 | 16.0 |
Pyruvic Acid | 3 | 23.0 |
Fibroblasts/*enzymology | 2 | 5.0 |
Lactates/blood | 2 | 2.0 |
Lactic Acid | 2 | 3.0 |
Lymphocytes/enzymology | 2 | 2.0 |
*Pyruvate Dehydrogenase Complex Deficiency Disease | 3 | 100.0 |
Japan/epidemiology | 2 | 0.0 |
Immunologic Techniques | 2 | 0.0 |
Fibroblasts/enzymology | 4 | 2.0 |
Carboxy-Lyases/*deficiency | 2 | 33.0 |
Pyruvate Decarboxylase/*deficiency | 2 | 100.0 |
Protein Kinases/*metabolism | 2 | 0.0 |
Mice, Inbred C57BL | 2 | 0.0 |
T-Lymphocytes/immunology | 3 | 0.0 |
Transcription, Genetic | 2 | 0.0 |
